Home » Topics » BioWorld Science

BioWorld Science
RSS

Can-Fite updates status of phase II trial of namodenoson in advanced HCC

June 20, 2018

Seattle Children's initiates phase I trial of CAR T-cell therapy for pediatric CNS tumors

June 20, 2018

Monalizumab shows promising activity in combination with durvalumab in MSS-CRC

June 20, 2018

Andes-1537 well tolerated in phase I study, dose expansions planned

June 20, 2018

Genentech, Roche and Paraza Pharma patent TRPA1 antagonists

June 20, 2018

Allena Pharmaceuticals completes preclinical proof-of-concept study for ALLN-346

June 20, 2018

Boehringer Ingelheim identifies free fatty acid receptor 1 agonists

June 20, 2018

RC-48-ADC demonstrates promising antitumor activity in patients with metastatic breast cancer

June 20, 2018

FDA grants regenerative medicine advanced therapy designation to CD34+ cell therapy

June 20, 2018

Positive interim phase II data presented for LB-1148 in patients undergoing major surgery

June 20, 2018

Popular Stories

Today's news in brief
BioWorld
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...
New mechanism of action identified for QC-6352
BioWorld Science
QC-6352 is a small molecule developed to inhibit the histone demethylase 4 (KDM4) that has shown potent antitumoral activity and which has a derivative named...
VST Bio’s VB-001 is neuroprotector after stroke
BioWorld Science
At the recent International Stroke Conference, researchers from VST Bio Corp. and Yale University presented preclinical data regarding VB-001, a monoclonal...